Proteomics International Laboratories Ltd (PIQ) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Proteomics International Laboratories Ltd (PIQ) has a cash flow conversion efficiency ratio of -0.416x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-5.40 Million ≈ $-3.82 Million USD) by net assets (AU$12.97 Million ≈ $9.18 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Proteomics International Laboratories Ltd - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Proteomics International Laboratories Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read PIQ liabilities breakdown for a breakdown of total debt and financial obligations.
Proteomics International Laboratories Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Proteomics International Laboratories Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Seni Jaya Corporation Bhd
KLSE:9431
|
0.050x |
|
Marti Otel Isletmeleri AS
IS:MARTI
|
-0.004x |
|
Tubos Reunidos S.A
MC:TRG
|
0.523x |
|
PTL LTD Ordinary Shares
NASDAQ:PTLE
|
-0.987x |
|
Horizon Space Acquisition I Corp. Ordinary Shares
NASDAQ:HSPO
|
0.000x |
|
YNH Property Bhd
KLSE:3158
|
0.084x |
|
Quickstep Holdings Ltd
AU:QHL
|
2.197x |
|
Telcon Inc
KQ:200230
|
0.004x |
Annual Cash Flow Conversion Efficiency for Proteomics International Laboratories Ltd (2014–2025)
The table below shows the annual cash flow conversion efficiency of Proteomics International Laboratories Ltd from 2014 to 2025. For the full company profile with market capitalisation and key ratios, see PIQ stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | AU$12.97 Million ≈ $9.18 Million |
AU$-6.60 Million ≈ $-4.67 Million |
-0.509x | +15.78% |
| 2024-06-30 | AU$9.25 Million ≈ $6.54 Million |
AU$-5.59 Million ≈ $-3.96 Million |
-0.605x | +11.59% |
| 2023-06-30 | AU$8.32 Million ≈ $5.89 Million |
AU$-5.69 Million ≈ $-4.03 Million |
-0.684x | +34.43% |
| 2022-06-30 | AU$3.39 Million ≈ $2.40 Million |
AU$-3.54 Million ≈ $-2.50 Million |
-1.043x | -259.29% |
| 2021-06-30 | AU$7.61 Million ≈ $5.38 Million |
AU$-2.21 Million ≈ $-1.56 Million |
-0.290x | -235.07% |
| 2020-06-30 | AU$4.44 Million ≈ $3.14 Million |
AU$-384.51K ≈ $-272.06K |
-0.087x | +84.48% |
| 2019-06-30 | AU$2.99 Million ≈ $2.11 Million |
AU$-1.67 Million ≈ $-1.18 Million |
-0.558x | -140.84% |
| 2018-06-30 | AU$4.68 Million ≈ $3.31 Million |
AU$-1.08 Million ≈ $-766.91K |
-0.232x | +74.63% |
| 2017-06-30 | AU$1.61 Million ≈ $1.14 Million |
AU$-1.47 Million ≈ $-1.04 Million |
-0.914x | +52.09% |
| 2016-06-30 | AU$791.42K ≈ $559.98K |
AU$-1.51 Million ≈ $-1.07 Million |
-1.907x | -408.33% |
| 2015-06-30 | AU$1.81 Million ≈ $1.28 Million |
AU$-677.26K ≈ $-479.21K |
-0.375x | -469.06% |
| 2014-06-30 | AU$4.94 Million ≈ $3.50 Million |
AU$-325.72K ≈ $-230.47K |
-0.066x | -- |
About Proteomics International Laboratories Ltd
Proteomics International Laboratories Ltd operates as a medical technology company with a focus on the area of proteomics in Australia, New Zealand, the United States, Europe, India, and Southeast Asia. It provides PromarkerD, a blood test to predict diabetic kidney disease (DKD). The company's products under development include PromarkerEndo, which has completed clinical validation phase for end… Read more